Effect of three months' treatment with irbesartan on blood and pulse pressure of hypertensive type 2 diabetic patients: open, observational study in 31793 patients

By Strutz F.   Bramlage P.   Paar W. D.  

Current Medical Research and Opinion, Vol. 21, Iss. 9, 2005-09 ,pp. : 1433-1440

Informa Healthcare

Access to resources Recommend Favorite

Estimation of cardiovascular risk in hypertensive patients in primary care

By Montgomery Alan A.   Fahey Tom   MacKintosh Christopher   Sharp Deborah J.   Peters Tim J.  

British Journal of General Practice, Vol. 50, Iss. 451, 2000-02 ,pp. : 127-128

Royal College of General Practitioners

Access to resources Recommend Favorite

Older type 2 diabetic patients are more likely to achieve glycaemic and cardiovascular risk factors targets than younger patients: analysis of a primary care database

By  

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol. 69, Iss. 12, 2015-12 ,pp. : 1486-1495

John Wiley & Sons Inc

Access to resources Recommend Favorite

Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study

By Persson Frederik   Rossing Peter   Hovind Peter   Stehouwer Coen   Schalkwijk Casper   Tarnow Lise   Parving Hans-Henrik  

Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 68, Iss. 8, 2008-01 ,pp. : 731-738

Informa Healthcare

Access to resources Recommend Favorite

Cost‐effectiveness analysis of adding pharmacists to primary care teams to reduce cardiovascular risk in patients with Type 2 diabetes: results from a randomized controlled trial

By  

DIABETIC MEDICINE, Vol. 32, Iss. 7, 2015-07 ,pp. : 899-906

John Wiley & Sons Inc

Access to resources Recommend Favorite